Literature DB >> 7644398

Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.

J Singh1, A Arora, P K Garg, V S Thakur, J N Pande, R K Tandon.   

Abstract

Antituberculosis drug-induced hepatotoxicity is quite common. However, factors predicting its development are still controversial. The objective of the present study was to evaluate the role of certain factors (age and sex of the patient, alcoholism, chronic liver disease, hepatitis B virus carrier status, acetylator status, nutritional status and antituberculosis treatment (ATT) regimen) in predicting the development of ATT-induced hepatitis. In a case-control study, 60 consecutive patients with evidence of ATT-induced hepatitis were studied to assess the possible association of the above-mentioned factors with ATT-induced hepatitis. Body mass index was found to be significantly lower in ATT-induced hepatitis patients (17.2 +/- 2.7) than in controls (19.5 +/- 3.3) (p < 0.05). Pyrazinamide was used in addition to isoniazid and rifampicin in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) as compared with those in the control group (42%). No significant differences were observed between the two groups with regard to the rest of the parameters.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644398      PMCID: PMC2398146          DOI: 10.1136/pgmj.71.836.359

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  26 in total

1.  Isoniazid, rifampin, and hepatotoxicity.

Authors:  P R Gangadharam
Journal:  Am Rev Respir Dis       Date:  1986-06

2.  Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.

Authors:  P Gurumurthy; M S Krishnamurthy; O Nazareth; R Parthasarathy; G R Sarma; P R Somasundaram; S P Tripathy; G A Ellard
Journal:  Am Rev Respir Dis       Date:  1984-01

3.  Hepatotoxicity of isoniazid and rifampin in children.

Authors:  P S Rugmini; S Mehta
Journal:  Indian Pediatr       Date:  1984-02       Impact factor: 1.411

4.  Hepatotoxicity of antituberculous drugs.

Authors:  N K Rao; R S Wadia; S R Karve; K B Grant
Journal:  J Assoc Physicians India       Date:  1982-05

5.  Isoniazid prophylaxis in hepatitis B carriers.

Authors:  K A McGlynn; E D Lustbader; R G Sharrar; E C Murphy; W T London
Journal:  Am Rev Respir Dis       Date:  1986-10

6.  Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.

Authors:  A K Dutt; D Moers; W W Stead
Journal:  Am J Med       Date:  1984-08       Impact factor: 4.965

Review 7.  The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.

Authors:  D J Girling
Journal:  Tubercle       Date:  1978-03

8.  Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.

Authors:  R J O'Brien; M W Long; F S Cross; M A Lyle; D E Snider
Journal:  Pediatrics       Date:  1983-10       Impact factor: 7.124

9.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

Authors:  D E Kopanoff; D E Snider; G J Caras
Journal:  Am Rev Respir Dis       Date:  1978-06

10.  Isoniazid pharmacokinetics in kwashiorkor.

Authors:  N Buchanan; C Eyberg; M D Davis
Journal:  S Afr Med J       Date:  1979-08-25
View more
  13 in total

1.  Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.

Authors:  Tarjinder Sahota; Oscar Della Pasqua
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

2.  Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.

Authors:  A C Anand; A K Seth; M Paul; P Puri
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 4.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

5.  Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review.

Authors:  Fahmi Yousef Khan; Fatima Rasoul
Journal:  Indian J Crit Care Med       Date:  2010-04

6.  Tuberculosis chemotherapy in the 21 century: Back to the basics.

Authors:  Jyotsna M Joshi
Journal:  Lung India       Date:  2011-07

Review 7.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

8.  A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.

Authors:  Chote Luangchosiri; Ammarin Thakkinstian; Sermsiri Chitphuk; Wasana Stitchantrakul; Supanna Petraksa; Abhasnee Sobhonslidsuk
Journal:  BMC Complement Altern Med       Date:  2015-09-23       Impact factor: 3.659

9.  Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism.

Authors:  Mohammad Sistanizad; Ebrahim Azizi; Hosein Khalili; Mahboobeh Hajiabdolbaghi; Kheirollah Gholami; Reza Mahjub
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

10.  Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients.

Authors:  Fang Liu; An-xia Jiao; Xi-rong Wu; Wei Zhao; Qing-qin Yin; Hui Qi; Wei-wei Jiao; Jing Xiao; Lin Sun; Chen Shen; Jian-ling Tian; Dan Shen; Evelyne Jacqz-Aigrain; A-dong Shen
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.